SCHEMBL4287851

SCHEMBL4287851

Nc1ccc(C(=O)Nc2nccs2)cc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.63
NPC1 O15118 8/20 0.63
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
SCD O00767 1/20 0.61
SMN1; SMN2 Q16637 4/20 0.60
LMNA P02545 1/20 0.60
RECQL P46063 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
KCNK3 O14649 1/20 0.59
KCNK9 Q9NPC2 1/20 0.59
SIRT2 Q8IXJ6 1/20 0.58
ALDH1A1 P00352 4/20 0.57
GAA P10253 1/20 0.57
POLB P06746 2/20 0.56
MAPT P10636 1/20 0.56
ESR2 Q92731 1/20 0.56
HSD17B10 Q99714 1/20 0.56
GCK P35557 1/20 0.56
MAPK8 P45983 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956673 0.83 RAB9A (0.71) RAB9ANPC1MEN1KMT2ASCD
SCHEMBL3190864 0.80 RAB9A (0.66) RAB9ANPC1MEN1KMT2ASCD
SCHEMBL3200155 0.80 RAB9A (0.66) RAB9ANPC1MEN1KMT2ASCD
SCHEMBL3199881 0.80 RAB9A (0.66) RAB9ANPC1MEN1KMT2ASCD
SCHEMBL3206087 0.80 RAB9A (0.66) RAB9ANPC1MEN1KMT2ASCD
SCHEMBL995829 0.78 NPC1 (1.00) RAB9ANPC1MEN1KMT2ASCD
SCHEMBL4290401 0.78 NPC1 (0.61) RAB9ANPC1MEN1KMT2ASCD
Hydrochloric Acid SCHEMBL27594584 0.77 NPC1 (0.97) RAB9ANPC1MEN1KMT2ASCD
SCHEMBL22348631 0.77 NPC1 (0.69) RAB9ANPC1MEN1KMT2ASCD
SCHEMBL4636379 0.77 NPC1 (0.73) RAB9ANPC1MEN1KMT2ASCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885MEN1 3248/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885MEN1 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.